Boston Scientific Corporation (FRA:BSX)
Germany · Delayed Price · Currency is EUR | Market Cap | 122.57B |
| Revenue (ttm) | 15.75B |
| Net Income (ttm) | 2.13B |
| Shares Out | n/a |
| EPS (ttm) | 1.43 |
| PE Ratio | 57.46 |
| Forward PE | 30.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7 |
| Average Volume | 9,918 |
| Open | 83.00 |
| Previous Close | 82.40 |
| Day's Range | 82.40 - 83.00 |
| 52-Week Range | 75.00 - 104.00 |
| Beta | n/a |
| RSI | 36.38 |
| Earnings Date | Oct 22, 2025 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]
Financial Performance
In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.
Financial numbers in USD Financial StatementsNews
Johnson & Johnson, Boston Scientific to Headline MEDevice Boston 2025 Keynote Sessions
BOSTON, MA / ACCESS Newswire / September 23, 2025 / MEDevice Boston, the premier MedTech event connecting top OEMs (Original Equipment Manufacturers) with emerging suppliers and strategic partners, ha...
Top 3 Health Care Stocks That May Explode In September
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go ...
Top 3 Health Care Stocks That May Explode In September
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Noteworthy Tuesday Option Activity: BSX, FDX, PYPL
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Boston Scientific Corp. (Symbol: BSX), where a total of 39,928 contracts have traded so far, rep...
Relative Strength Alert For Boston Scientific
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Boston Scientific Breaks Below 200-Day Moving Average - Notable for BSX
In trading on Monday, shares of Boston Scientific Corp. (Symbol: BSX) crossed below their 200 day moving average of $100.54, changing hands as low as $100.39 per share. Boston Scientific Corp. shares ...
Peter Lynch Detailed Fundamental Analysis - BSX
Below is Validea's guru fundamental report for BOSTON SCIENTIFIC CORP (BSX). Of the 22 guru strategies we follow, BSX rates highest using our P/E/Growth Investor model based on the published strategy ...
Pre-tax profits at Irish arm of Boston Scientific increase by 52pc to $111m
Pre-tax profits at the main Irish arm of medical device manufacturer Boston Scientific last year increased by 52pc to $111.15m (94.8m).
Elutia (ELUT) Sells Bioenvelopes to Boston Scientific
Elutia (ELUT) Sells Bioenvelopes to Boston Scientific
Boston Scientific (BSX) Purchases Elutia's Bioenvelope Assets in $88 Million Deal
Boston Scientific (BSX) Purchases Elutia's Bioenvelope Assets in $88 Million Deal
Boston Scientific buys Elutia's bioenvelope business for $88 million
Boston Scientific Corporation (BSX) Announces Executive Retirement
Boston Scientific Corporation (BSX) Announces Executive Retirement
Boston Scientific announces 2025 Investor Day meeting and conference call discussing third quarter 2025 results
MARLBOROUGH, Mass. , Sept. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategi...
How Do Investors Really Feel About Boston Scientific?
Boston Scientific's (NYSE: BSX) short percent of float has risen 14.55% since its last report. The company recently reported that it has 18.60 million shares sold short , which is 1.26% of all regula...
8 Growth Stocks to Buy That Aren't Technology. What Makes Them Worth It.
As tech stocks float at historic highs, it's a good time to look elsewhere for growth. A Citi screen turned up eight names that are mostly outside the tech sector.
IBD Stock Of The Day Boston Scientific Breaks Out — Here's Why
Boston Scientific is Wednesday's IBD Stock Of The Day. Shares are breaking a short-term trendline at their 50-day moving average.
Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 10 Years
Boston Scientific (NYSE: BSX) has outperformed the market over the past 10 years by 7.53% on an annualized basis producing an average annual return of 20.65%. Currently, Boston Scientific has a marke...
Boston Scientific Stock Hits A Record High, Consolidates. Prepping For Another Run?
Boston Scientific shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Boston Scientific Corporation Is Expensive But Worth It
Boston Scientific’s AI leadership, global growth, and strong R&D make it a long-term winner despite valuation and regulatory risks. See why BSX stock is a buy.
Boston Scientific Reports 16 Deaths Linked To Defibrillator Lead Issue
The Food and Drug Administration (FDA) said on Wednesday it is monitoring a potential safety issue involving Boston Scientific Corporation’s (NYSE: BSX) ENDOTAK RELIANCE defibrillation leads, followi...
Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...
Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions
LONDON & BOSTON--(BUSINESS WIRE)--Keyron appoints former FDA and Boston Scientific leaders as ForePass—a breakthrough device for severe metabolic disease—prepares for clinical trials.
10 stocks favored to gain up to 30% in a sector that has missed this year's rally
All but two of the S&P 500's sectors are up so far in 2025.
What's Driving the Market Sentiment Around Boston Scientific?
Boston Scientific's (NYSE: BSX) short percent of float has risen 3.1% since its last report. The company recently reported that it has 19.57 million shares sold short , which is 1.33% of all regular ...
This health care stock forming a 'big base breakout' is ready to separate from the pack, charts indicate
David Keller breaks down the charts in Boston Scientific.